The panel allowed the detection of the pathogenic mutations in well-established CRC susceptibility genes, such as APC, MLH1, and MSH6 in high-penetrance genes, and in moderate-penetrance genes like MUTYH (monoallelic), BMPR1A, BLM, and CHEK2 in 11 patients (8.8%) of our cohort. This evidence concerns the gene BLM and colorectal carcinoma.